EP2235032A2 - Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis - Google Patents

Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis

Info

Publication number
EP2235032A2
EP2235032A2 EP08763854A EP08763854A EP2235032A2 EP 2235032 A2 EP2235032 A2 EP 2235032A2 EP 08763854 A EP08763854 A EP 08763854A EP 08763854 A EP08763854 A EP 08763854A EP 2235032 A2 EP2235032 A2 EP 2235032A2
Authority
EP
European Patent Office
Prior art keywords
oleuropein
products
peracylation
chemical
hydrolysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08763854A
Other languages
German (de)
French (fr)
Inventor
Antonio Procopio
Giovanni Sindona
Nicola Costa
Marco Gaspari
Monica Nardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi "Magna Graecia" di Catanzaro
Universita della Calabria
Original Assignee
Universita degli Studi "Magna Graecia" di Catanzaro
Universita della Calabria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20070903 external-priority patent/ITMI20070903A1/en
Priority claimed from ITMI20070904 external-priority patent/ITMI20070904A1/en
Application filed by Universita degli Studi "Magna Graecia" di Catanzaro, Universita della Calabria filed Critical Universita degli Studi "Magna Graecia" di Catanzaro
Publication of EP2235032A2 publication Critical patent/EP2235032A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the method, object of the present invention regards a method for the chemical manipulation of oleuropein and its synthetic products using Lewis acidic catalysts with a low environmental impact, in order to obtain a new class of molecules that are biologically active, such as anti-oxidants and anti-inflammatory ones.
  • oleuropein and its synthetic products using Lewis acidic catalysts with a low environmental impact, in order to obtain a new class of molecules that are biologically active, such as anti-oxidants and anti-inflammatory ones.
  • phenolic compounds of the olive are distributed in all the parts of the plant, but their nature and concentration vary greatly among the various tissues.
  • hydroxytyrosol and oleuropein (Fig. 1) that represent the predominant phenolic compound and which can reach concentrations of 140 mg/g in dried green olives and 60-90 mg/g in the dried leaves; studies in vitro have demonstrated that oleuropein and hydroxytyrosol carry out an anti-tumour activity.
  • the selective hydrolysis of the glycosidic bond of oleuropein is a process that occurs naturally in the olive drupes, caused by the endogenous ⁇ - glucosidase.
  • Enzymatic hydrolysis with glycosidase the oleuropein (5g) is dissolved in 500 ml ⁇ bf buffer water at pH 5.0 and treated with glycosidase until the mixture of reaction monitored by t.l.c. indicates the complete disappearance of the oleuropein. After the classic treatment of the mixture of reaction, the chromatographic purification gives the various products of the hydrolysis of the oleuropein.
  • the present invention proposes to overcome the difficulties and the disadvantages present in the solutions at use at present.
  • the discovery object of the present application can be considered a technique that overcomes and resolves the problems tied to the quantitative yield of the products and to the use of non-recyclable catalysts, that are highly toxic and expensive.
  • the principal aim of the invention is to create a chemical-catalytic method for the peracylation of oleuropein and of its synthetic products, characterised by the fact that it comprises the following phases:
  • oleuropein or one of its products from hydrolisis is placed to react in the presence of Lewis acid catalysts directly with acylating agents that contain at least one acylic group R, where R is H, an alkenilic radical of 1-31 linear or branched atoms of carbon, an alkenilic radical containing up to 31 atoms of carbon or an aryl group;
  • reaction is treated by adding a volume of hydrolysis agents of the acylating type (alcohol, water, etc.) that is agitated, at the end of which the solvent is dried under reduced pressure, leaving a residue.
  • acylating type alcohol, water, etc.
  • the residue is revived in an organic solvent and extracted at least twice with water; the organic phases collected are dried on anhydrous Na2SO4 and evaporated; the basic product obtained is purified by flash chromatography on a column of silica gel.
  • Lewis acid catalysts are halides and triflates of lanthanides (III).
  • the oleuropein is made to react in a reflux aqueous organic solvent in the presence of triflates or halides of lanthanides (III) as Lewis acid catalysts.
  • Lewis acid catalysts are halides and triflates (trifluoromethanesulfonates) of lanthanides (III).
  • the innovative and inventive contribution is given by the peracylation of the oleuropein and its synthetic products, the aglycon and the hydroxytyrosol, that provide a new class of molecule that are biologically active as anti-oxidants and antiinflammatory.
  • object of patent application consists of a first phase characterised by the hydrolysis of the oleuropein finalised by the synthesis of its aglycon and/or the hydroxytyrosol.
  • the characterisation of the aglycon demonstrates that what is chromatographically separable as a single fraction is, actually, a mixture of at least three tautomeric forms (compounds 4-6, Figure 3), plus a hydrated form (compound 8, Figure 3) and a methanolated form (compound 7, Figure 3), as has been ascertained by NMR structural analysis and by mass spectrometry.
  • hydroxytyrosol is obtained by known techniques. It will later be used as the crude base (with a yield of 90%) for the acetylation, while only a small part is cromato graphically purified (eluent mixture CH 2 Cl 2 /Me0H 9.5/0.5 v/v).
  • the procedure consists of a second phase, characterised by the peracylation of the above-mentioned components to obtain, respectively, the oleuropein acylate ( Figure 6 shows as an example, the acetylisation) and a new class of molecules that are biologically active as anti-oxidants or anti-inflammatory ones (Figure 5).
  • the synthetic strategy takes profit from the excellent properties of the halides and triflates of lanthanides (I ⁇ I)cas Lewis acid catalysts.
  • the component is placed to react, in the presence of catalytic quantities of Lewis acid, directly with an acylating agent containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group.
  • the peracetylated compounds 6d and 6e with the highest molecular weight deriving, one from a methanolated form and the other from a hydrated form of the initial aglycon, are the primary products of the reaction;
  • the diacetylated compound 6a is present only in small quantities in the mixture;
  • the acetylisation effectively freezes the composition of equilibrium of the aglycon at the beginning of the reaction and the products of the acetylisation do not interconvert with each other during the course of the reaction itself.
  • the proven anti-oxidant activity of oleuropein and its derivatives has led to the hypothesis that they could also act as a protection against oxidative stress at the level of the central nervous system, one of the causal factors of Parkinson's disease.
  • the acetylated derivatives of the oleuropein, the aglycon and the hydroxytyrosol are more efficient with respect to the non-acetylated molecules, with a particular relevancy for the acetylated aglycon, which has a protection factor that is higher than 80% at the concentration of only l ⁇ g/ ⁇ L; at the concentration of 10 ⁇ g/ ⁇ L all the acetylated molecules have a total protection factor while the aglycon and hydroxytyrosol demonstrate a survival percentage greater than, or equal to, 80%.
  • the present invention permits numerous advantages and to overcome difficulties that cannot be overcome with the systems on sale at present.

Abstract

The method, object of the present invention, concerns the peracylation of oleuropein and its products of hydrolysis: The method makes use of the excellent properties as Lewis acid catalysts of halides and tryphilates of lanthanides (III). The component is placed to react, in the presence of catalytic quantities of Lewis acid, directly with an acylating agent containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group. The procedures for the extraction and the successive hydrolysis of the oleuropein for the synthesis of its aglycon and the hydroxytyrosol, resolve the problems tied to the quantitative yield of the products and to the use of highly-toxic and expensive catalysts. Furthermore, the innovative and inventive contribution is given by the peracylation of the oleuropein and its products of synthesis, aglycon and hydroxytyrosol, that supply a new class of molecule, biologically active as anti-oxidants and anti-inflammatory ones. The proven anti-oxidant activity of oleuropein and its derivates leads to the hypothesis that they could also act as protectors against oxidative stress at the level of the central nervous system, one of the causal factors of Parkinson's disease. The molecules examined are all good protectors against oxidative stress and the greater efficiency of the peracylated derivatives is presumably due to their greater lipophilicity and the possibility of penetrating the cellular membrane.

Description

Chemical-catalytic method for the peracylation of oleuropein and its
products of hydrolysis Technical field of the invention
The method, object of the present invention, regards a method for the chemical manipulation of oleuropein and its synthetic products using Lewis acidic catalysts with a low environmental impact, in order to obtain a new class of molecules that are biologically active, such as anti-oxidants and anti-inflammatory ones. State of the art
An ever increasing interest for phenolic compounds is due to their anti-oxidant properties and their many beneficial effects on human health. The phenolic compounds of the olive are distributed in all the parts of the plant, but their nature and concentration vary greatly among the various tissues.
In Olea Enropaea we find hydroxytyrosol and oleuropein (Fig. 1) that represent the predominant phenolic compound and which can reach concentrations of 140 mg/g in dried green olives and 60-90 mg/g in the dried leaves; studies in vitro have demonstrated that oleuropein and hydroxytyrosol carry out an anti-tumour activity.
Notwithstanding this, it is rare to find oleuropein in extra-virgin olive oil and many authors have suggested that this is due to the various decays to which the same oleuropein is subject during the working of the olives, when, an endogenous β- glucosidase selectively hydrolyses the glycosidic bond of the oleuropein transforming it into its aglycon (Fig.2), a complex mixture of tautomers with multiple biological activities.
These compounds protect against the formation of artereo-sclerotic lesions; furthermore in vitro studies have demonstrated that these derivatives carry out various biological activities (anti-microbe, in anti-platelet drugs, with vasodilators, with hypertension, with hyperglycaemia, etc.) that very often are connected to their activities as scavengers of free radicals.
To form its aglycon the selective hydrolysis of the glycosidic bond of oleuropein is a process that occurs naturally in the olive drupes, caused by the endogenous β- glucosidase.
It is difficult, however, to reproduce said selective hydrolysis synthetically, due to the presence, on the molecule of oleuropein, of multiple acidic functions or faint traces of such, other than the glycoside bond. On the other hand, methods of controlled chemical manipulation capable of supplying its derivatives do not exist.
In this sector diverse techniques of hydrolysis are well-known, such as:
• Acid hydrolysis: The oleuropein (0.5g) is dissolved in 100 ml Of H2SO4 IN and heated to 100°C for 1 hour. The mixture of reaction is therefore cooled, brought to pH 2.0 and extracted with ethyl acetate." The basic product thus obtained, purified by chromatography gave hydroxytyrosol (65 mg), elenoic acid (15 mg) and the aglycon of the oleuropein (14 mg) in very low yields.
• Alkaline hydrolysis: The oleuropein (Ig) is dissolved in 50 ml of methanol. The stirred solution is cooled to 10°C and treated with approximately 2g of potassium hydroxide in tablets. The mixture of reaction is allowed to warm to room temperature and after about 6 hours, the same mixture is diluted with approximately 60 ml of HCl 6N (pH of about 7.5) and then dried by evaporation. The chromatographic purification of the mixture of products thus obtained gave the oleoside as main product.
These techniques present, however, some inconveniences or problems linked to the scarce quantitative yields of aglycon of the oleuropein, and to the used catalyst that result toxic and non-recyclable.
Some solutions have been proposed to partially avoid the above-mentioned drawbacks, the object of the Patent request US6117844 having as its basic element the following technique:
• Enzymatic hydrolysis with glycosidase: the oleuropein (5g) is dissolved in 500 ml^bf buffer water at pH 5.0 and treated with glycosidase until the mixture of reaction monitored by t.l.c. indicates the complete disappearance of the oleuropein. After the classic treatment of the mixture of reaction, the chromatographic purification gives the various products of the hydrolysis of the oleuropein.
Neither the state of the technique in use at present nor the existing patented solutions overcome the above-cited critical aspects, however. Presentation of the invention
The present invention proposes to overcome the difficulties and the disadvantages present in the solutions at use at present.
In particular, the discovery object of the present application, can be considered a technique that overcomes and resolves the problems tied to the quantitative yield of the products and to the use of non-recyclable catalysts, that are highly toxic and expensive.
The principal aim of the invention is to create a chemical-catalytic method for the peracylation of oleuropein and of its synthetic products, characterised by the fact that it comprises the following phases:
• oleuropein or one of its products from hydrolisis is placed to react in the presence of Lewis acid catalysts directly with acylating agents that contain at least one acylic group R, where R is H, an alkenilic radical of 1-31 linear or branched atoms of carbon, an alkenilic radical containing up to 31 atoms of carbon or an aryl group;
• the reaction is treated by adding a volume of hydrolysis agents of the acylating type (alcohol, water, etc.) that is agitated, at the end of which the solvent is dried under reduced pressure, leaving a residue.
The residue is revived in an organic solvent and extracted at least twice with water; the organic phases collected are dried on anhydrous Na2SO4 and evaporated; the basic product obtained is purified by flash chromatography on a column of silica gel.
Another characteristic is given by the fact that the Lewis acid catalysts are halides and triflates of lanthanides (III).
Another characteristic is given by the fact that the residue is revived in an organic solvent and is extracted three times with water.
Another characteristic is given by the fact that the oleuropein is manipulated to synthesize its aglycon and the hydroxy-tirosol.
Another characteristic is given by the fact that the manipulation of the oleuropein comprises the following phases:
• hi order to chemically degrade it in a controlled manner, the oleuropein is made to react in a reflux aqueous organic solvent in the presence of triflates or halides of lanthanides (III) as Lewis acid catalysts.
• the reaction is terminated by adding a few ml of H2O and the product is extracted three times in CH2CI2;
• The united organic phases are dried on anhydrous Na2SO4 and evaporated; Another characteristic is given by the fact that the Lewis acid catalysts are halides and triflates (trifluoromethanesulfonates) of lanthanides (III).
Above all, the innovative and inventive contribution is given by the peracylation of the oleuropein and its synthetic products, the aglycon and the hydroxytyrosol, that provide a new class of molecule that are biologically active as anti-oxidants and antiinflammatory.
After having extracted the oleuropein from the leaves of the olive the procedure, object of patent application, consists of a first phase characterised by the hydrolysis of the oleuropein finalised by the synthesis of its aglycon and/or the hydroxytyrosol.
The characterisation of the aglycon demonstrates that what is chromatographically separable as a single fraction is, actually, a mixture of at least three tautomeric forms (compounds 4-6, Figure 3), plus a hydrated form (compound 8, Figure 3) and a methanolated form (compound 7, Figure 3), as has been ascertained by NMR structural analysis and by mass spectrometry.
The components of the mixture, visible by HPLC analysis as five distinct peaks are due to, on the one hand, the tautomeric equilibrium of a dialdehydic form (compound 5, Figure 3), capable of rapidly inter-converting itself into its enolic form (compound 4, Figure 3) and into the closed form (compound 6, Figure 3), and on the other hand from the nucleophilic attack from the water (present in the environment of the reaction) and from methanol (present in the eluent phase) on the aldehyde carbon, to give the hydrated form (compound 7, Figure 3) and the methanolated form (compound 8, Figure
3).
The 1H-NMR analysis of the mixture demonstrates that the tautomeric form present in greatest quantity at equilibrium is the dialdehydic form, as seen from the doublet at 9.56 and 9.53 ppm, characteristic of the two aldehydic protons, while the peaks which are characteristic of the two remaining tautomers can also be seen in lesser quantities.
From the LC/MS-ESI analysis can be noted, finally, the presence of three significant peaks of three different m/z values, that are attributable to the proton forms of the tautomers (all the tautomers have the same mass and therefore contribute to the same peak), of the hydrated molecule and the methanolated molecule.
The hydroxytyrosol, however, is obtained by known techniques. It will later be used as the crude base (with a yield of 90%) for the acetylation, while only a small part is cromato graphically purified (eluent mixture CH2Cl2/Me0H 9.5/0.5 v/v).
After obtaining the oleuropein, its aglycon and the hydroxytyrosol, the procedure consists of a second phase, characterised by the peracylation of the above-mentioned components to obtain, respectively, the oleuropein acylate (Figure 6 shows as an example, the acetylisation) and a new class of molecules that are biologically active as anti-oxidants or anti-inflammatory ones (Figure 5).
In particular, for the peracylation of the above-mentioned components, the synthetic strategy takes profit from the excellent properties of the halides and triflates of lanthanides (IΙI)cas Lewis acid catalysts. The component is placed to react, in the presence of catalytic quantities of Lewis acid, directly with an acylating agent containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group.
In the mixture obtained from the peracylation of the aglycon at least 5 compounds that are diversely acylated are present (componds 6 a-e, Figure 5); the peracetylated compounds 6d and 6e with the highest molecular weight deriving, one from a methanolated form and the other from a hydrated form of the initial aglycon, are the primary products of the reaction; the diacetylated compound 6a is present only in small quantities in the mixture; the acetylisation effectively freezes the composition of equilibrium of the aglycon at the beginning of the reaction and the products of the acetylisation do not interconvert with each other during the course of the reaction itself. The proven anti-oxidant activity of oleuropein and its derivatives has led to the hypothesis that they could also act as a protection against oxidative stress at the level of the central nervous system, one of the causal factors of Parkinson's disease. The acetylated derivatives of the oleuropein, the aglycon and the hydroxytyrosol are more efficient with respect to the non-acetylated molecules, with a particular relevancy for the acetylated aglycon, which has a protection factor that is higher than 80% at the concentration of only lμg/μL; at the concentration of 10 μg/μL all the acetylated molecules have a total protection factor while the aglycon and hydroxytyrosol demonstrate a survival percentage greater than, or equal to, 80%. It can be deduced that the molecules examined are all good protectors against oxidative stress and the greater efficiency of the peracetylated derivatives is presumably due to their greater lipophilicity and the possibility to penetrate the cellular membrane. The use of Lewis acid catalysis in the hydrolysis of the oleuropein for the synthesis of its aglycon and of the hydroxytyrosol presents numerous advantages as given here following:
• Synthetic: the derivation of the oleuropein makes use of innovative and renewable methods such as "green" processes, to save or eliminate organic solvents at the stage of synthesis and in the recovery of the catalysts, which are also of low-toxicity, at the treatment stage. The catalysts used are recyclable, of low-toxicity, economic, and are used precisely in catalytic quantities, presenting, therefore, an unquestionable advantage with regard to sulphuric acid or alkaline hydroxides used in high concentrations to obtain the aglyconic product in very low yield.
• quantitative: the Lewis acid catalysts proposed cause the selective hydrolysis of the glycosidic bond present in the molecule of the oleuropein thus permitting almost quantitative yields of the product;
• Environmental: the olive leaves, which until now represented waste in the olive- culture process of extraction of extra-virgin olive oil, become a source of primary material.
• Pharmaceutical: oleuropein and its derivatives, already preliminarily tested in vivo in laboratories as protectors against oxidative stress induced by Paraquat, will be subjected to biological tests in vitro and in vivo to demonstrate their activity as non-selective inhibitors of cyclo-oxygenase enzymes COX-I e COX- 2 and as the antiviral and antitumour entities.
In Figure 1 the Olea Europaea molecule is shown, and in which we find the oleuropein that represents the predominant phenolic compound and the hydroxytyrosol.
In Figure 2 the oleuropein is shown after having undergone, when an endogenous β- glucosidase that selectively hydrolyses the glicosidic bond of the oleuropein itself, the transformation of its aglycon, a complex mixture of tautomers with multiple biological activities.
In Figure 3 the procedure of synthesis of the oleuropein to obtain its aglycon as a mixture of three tautomeric forms, a hydrated form and a methanolated form is shown. In Figure 4 the hydroxytyrosol is shown, and which represents the hydroxy-phenolic part of the oleuropein.
In Figure 5 the procedure of synthesis of the oleuropein to obtain the hydroxytyrosbl and the successive acetylisation is shown.
In Figure 6 the acetylisation of the aglycon and the obtaining of diverse contents is shown.
The discovery, it must be noted, is not limited to the description given, but may be perfected and modified by those skilled in the art, without, however, departing from the limits of patent.
The present invention permits numerous advantages and to overcome difficulties that cannot be overcome with the systems on sale at present.
METHOD OF USE OF THE DISCOVERY
The discovery is illustrated in the following example that in no way limits the aim of the present invention.
EXAMPLE l
Acylation of oleuropein
500 mg of oleuropein (28.73 mmol) are placed in a 100 ml round bottomed flask with 10.0 ml of acetic anhydride and 3.0 mol % of catalyst. Then, it is magnetically stirred at room temperature.
After 2 hours 20.0 millilitres of methanol are added, and the solution is left to cool. All the solvent evaporates, and the residue, revived with dichloromethane is dried on sodium sulphate. The crude product, obtained after filtering and the evaporation of the solvent, is purified on a chromatographic column (eluent mixture dichloromethane/methanol = 9.50/0.50), obtaining a yield of 67%.

Claims

1. Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis, characterised by the fact that it comprises the following phases:
• oleuropein or one of its hydrolysis products is placed to react in the presence of
Lewis acid catalyst directly with acylating agents containing at least one acylic group R, where R is H, an alkylic radical of 1-31 atoms of linear or branched carbon, an alkenylic radical containing up to 31 atoms of carbon or an arylic group;
• the reaction is treated with the addition of a volume of hydrolysing agents of the acylant type (alcohol, water, etc.) and is stirred, at the end of which the solvent is dried under reduced pressure, leaving a residue;
• The residue is revived in an organic solvent and extracted with water at least twice; the organic phases gathered are dried on anhydrous Na2SO4 and evaporated; the raw product obtained is purified by flash chromatography on a column of silica gel.
2. Chemical-catalytic method for the peracylation of oleuropein and of its hydrolysis products according to claim 1, characterised by the fact that the Lewis acid catalysts are halides and triflates of lanthanides (III).
3. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to claims 1 or 2, characterised by the fact that the residue is revived in an organic solvent and extracted three times with water.
4. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to any of the preceding claims, characterised by the fact that the oleuropein is manipulated to syήthesise its aglycoh arid the hydroxy-tirosol.
5. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to the preceding claim, characterised by the fact that the manipulation of the oleuropein comprises the following phases:
• in order to chemically degrade in a controlled manner, the oleuropein is made to react in a reflux aqueous organic solvent, in the presence of Lewis acid catalysts of triflates or halides of lanthanides (III).
• the reaction is terminated by adding several ml of H2O and the product is extracted three times in CH2CI2 ;
• the united organic phases are dried on anhydrous Na2SO4 and evaporated;
6. Chemical-catalytic method for the peracylation of oleuropein and of its products of synthesis, according to the preceding claim, characterised by the fact that the Lewis acid catalysts are halides and triflates of lanthanides (III).
EP08763854A 2007-05-04 2008-05-05 Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis Withdrawn EP2235032A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20070903 ITMI20070903A1 (en) 2007-05-04 2007-05-04 CHEMICAL-CATALYTIC METHOD FOR THE PERACIVATION OF OLEUROPEINE AND ITS HYDROLYSIS PRODUCTS.
ITMI20070904 ITMI20070904A1 (en) 2007-05-04 2007-05-04 CHEMICAL-CATALYTIC METHOD FOR THE HANDLING OF OLEUROPEINE FOR THE SYNTHESIS OF ITS AGLICONE.
PCT/IT2008/000303 WO2008136037A2 (en) 2007-05-04 2008-05-05 Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis

Publications (1)

Publication Number Publication Date
EP2235032A2 true EP2235032A2 (en) 2010-10-06

Family

ID=39855088

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08763854A Withdrawn EP2235032A2 (en) 2007-05-04 2008-05-05 Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis

Country Status (2)

Country Link
EP (1) EP2235032A2 (en)
WO (1) WO2008136037A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102532217B (en) * 2011-12-23 2014-12-10 王刻铭 Method for purifying and separating high-content oleuropein from olive leaves
CN104341307B (en) * 2013-08-05 2016-12-28 北京京朋汇药业研究发展有限公司 Phenylacetic acid derivatives and anticancer usage thereof
ITUA20163706A1 (en) * 2016-05-23 2017-11-23 Univ Degli Studi Magna Graecia Di Catanzaro Method of peracylation of natural compounds
CN106187708A (en) * 2016-07-25 2016-12-07 西安岳达生物科技股份有限公司 A kind of preparation method of high-purity hydroxytyrosol
WO2019151299A1 (en) * 2018-02-02 2019-08-08 国立研究開発法人産業技術総合研究所 Method for producing glutaraldehyde derivative originating in natural material
CN110128246B (en) * 2019-06-10 2022-07-26 杭州志源生物科技有限公司 Preparation method of hydroxytyrosol
CN113277931A (en) * 2021-06-04 2021-08-20 陕西富恒生物科技有限公司 Method for extracting hydroxytyrosol from olive fruits

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4139196A (en) * 1994-11-07 1996-05-31 William R. Fredrickson Method and composition for antiviral therapy
WO2003082259A1 (en) * 2002-04-03 2003-10-09 Puleva Biotech, S.A. Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008136037A2 *

Also Published As

Publication number Publication date
WO2008136037A2 (en) 2008-11-13
WO2008136037A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2008136037A2 (en) Chemical-catalytic method for the peracylation of oleuropein and its products of hydrolysis
Rajput et al. Sulfuric acid immobilized on silica: an efficient reusable catalyst for the synthesis of O-isopropylidene sugar derivatives
Wolfrom et al. Configurational correlation of L-(levo)-glyceraldehyde with natural (dextro)-alanine by a direct chemical method
Kitanov et al. Benzophenone O-glucoside, a biogenic precursor of 1, 3, 7-trioxygenated xanthones in Hypericum annulatum
AU2008201553B2 (en) Composition for treating cancer cells and synthetic method for the same
CN101575300A (en) Production method of S-2-aminobutanamide
CN103374050B (en) One prepares 5,6, the method for 4 '-trihydroxyflavone-7-0-D-glucuronic acid
Kumar et al. Phenolic glycosides from Dodecadenia grandiflora and their glucose-6-phosphatase inhibitory activity
HRP20000054A2 (en) Improved process for antiparasitic agent
Mandal et al. Concise synthesis of two trisaccharides related to the saponin isolated from Centratherum anthelminticum
Xiao et al. Convenient Synthesis of D‐Talose from D‐Galactose
Oizumi et al. Synthesis of Procyanidins C2 and C1 Using Lewis Acid Mediated Equimolar Condensation
CN111978362B (en) Method for removing iso-naringin in natural product hesperidin
CN101990528B (en) Catechol manufacturing method
Pawar et al. Intramolecular reductive cyclization strategy to the synthesis of (−)-6-methyl-3-hydroxy-piperidine-2-carboxylic acid,(+)-6-methyl-(2-hydroxymethyl)-piperidine-3-ol and their glycosidase inhibitory activity
Pal et al. Synthesis of the tetrasaccharide repeating unit of the O-glycan from the polar flagellum flagellin of Azospirillum brasilense Sp7
Paradas et al. Clarifying the structure of granadaene: total synthesis of related analogue [2]-granadaene and confirmation of its absolute stereochemistry
CN107488144B (en) Molecule capable of specifically binding and inhibiting Tau protein aggregation and preparation method and application thereof
Šlapetová et al. Glycosylated nervogenic acid derivatives from Liparis condylobulbon (Reichb. f.) leaves
Kuo et al. An efficient synthesis of a potent anti-inflammatory agent, viscolin, and its inducible nitric oxide synthase inhibitory activity
Tisse et al. Selective access and full characterization of mono-acidic permethylated β-cyclodextrin derivatives and their methyl esters
Handayani et al. Synthesis and activity test as antioxidant of two hydroxydibenzalacetones
CN116574081B (en) Chlorogenic acid-Huang Qinsu conjugate and preparation method and application thereof
RU2755123C1 (en) (6r,8r,10s,12r,13ar)-5-methyl-3,6,7,8,9,10,11,12,13,13а-decahydro-1н-2,6: 6а,10:8,12-trimethanocyclonone[c]-azocine production method
CA2725842C (en) Process for the glycosidation of colchicine and thiocolchicine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20120612

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121023